title: [Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group].
abstract: Between 1998 and 1999, 36 children aged from 3 months to 18 years (10 girls and 26 boys) with first relapse of acute lymphoblastic leukaemia were included in the study. The children were treated according to the BFM 96 relapse protocol. There were 24 cases with early (including 9 children with very early) and 12 cases with late relapse ( BM-20, local extra BM-6, combined 10). The overall second complete remission (CR) rate was 83,33%. The probability of overall EFS after 2 years was 73,3%. The results obtained with BFM 96 chemotherapy in children with first late relapse are acceptable. For children with early relapses, megachemotherapy with BMT in second remission should be used.
authors.affiliation: Klinika Hematologii, i Chorob Rozrostowych Dzieci, 50-345 Wrocław, Bujwida 44, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: E
authors.initials: E
authors.lastname: Gorczyńska
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: H
authors.initials: H
authors.lastname: Bubala
authors.forename: B
authors.initials: B
authors.lastname: Filiks-Litwin
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: K
authors.initials: K
authors.lastname: Łukowska
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: E
authors.initials: E
authors.lastname: Rola-Kurc
authors.forename: D
authors.initials: D
authors.lastname: Stencel
authors.forename: D
authors.initials: D
authors.lastname: Sonta-Jakimczyk
authors.forename: W
authors.initials: W
authors.lastname: Strojny
authors.forename: J
authors.initials: J
authors.lastname: Wachowiak
authors.forename: M
authors.initials: M
authors.lastname: Wieczorek
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: E
authors.initials: E
authors.lastname: Zelenay
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011044:Poland; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use*; D012074:Remission Induction; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin